The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 28 February 2006, www.theannals.com, DOI 10.1345/aph.1E636.
 The Annals of Pharmacotherapy: Vol. 40, No. 3, pp. 461-471. DOI 10.1345/aph.1E636
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fong, J. J
Right arrow Articles by Rhoney, D. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fong, J. J
Right arrow Articles by Rhoney, D. H

NEW DRUG DEVELOPMENTS

NXY-059: Review of Neuroprotective Potential for Acute Stroke

Jeffrey J Fong, PharmD

Critical Care Pharmacy Fellow, Tufts–New England Medical Center, Northeastern University School of Pharmacy, Boston, MA

Denise H Rhoney, PharmD FCCP

Associate Professor, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit

Reprints: Dr. Rhoney, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201-2153, fax 313/577-5369, drhoney{at}wayne.edu

OBJECTIVE: To review available literature on the pharmacology, pharmacokinetics, efficacy, and tolerability of NXY-059, an investigational agent with a potential role in the treatment of acute stroke.

DATA SOURCES: Information was obtained from a MEDLINE search (1966–February 2006) of English-language literature utilizing the following search terms: NXY-059, cerovive, nitrones, neuroprotection, free radical trapper, and secondary neurologic injury.

STUDY SELECTION AND DATA EXTRACTION: Data from animal and human trials were evaluated to summarize the mechanism of action, efficacy, and safety of NXY-059. All published and unpublished trials and abstracts citing NXY-059 were selected.

DATA SYNTHESIS: NXY-059 is an intravenous, nitrone-based, free radical trapping agent in Phase III trials for treatment of acute stroke. In various animal models, NXY-059 has shown reductions in infarct volume and neurologic deficits. Pharmacokinetic studies indicate that NXY-059 displays a predictable pharmacokinetic profile and primarily undergoes renal elimination. Results from 2 Phase II clinical trials showed favorable results for the safety and tolerability of the drug. A recent analysis of one of the Phase III trials showed a statistically significant reduction in the primary outcome of disability after acute stroke in patients who received NXY-059 compared with placebo.

CONCLUSIONS: NXY-059 is a novel agent undergoing worldwide Phase III trials. Initial safety and efficacy data have not revealed any serious adverse events requiring special monitoring and/or precautions, with the exception of drug accumulation in patients with renal insufficiency. The potential benefit of this agent can change the current management algorithm for acute stroke and may represent significant advancement for the care of these patients.

Key Words: cerovive, neuroprotection, NXY-059, stroke

Published Online, February 28, 2006. www.theannals.com, DOI 10.1345/aph.1E636


This article has been cited by other articles:


Home page
 Arch NeurolHome page
A. I. Faden and B. Stoica
Neuroprotection: Challenges and Opportunities
Arch Neurol, June 1, 2007; 64(6): 794 - 800.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.